Which company offers a higher dividend yield?

Pfizer offers a higher dividend yield compared to AbbVie.

Does AbbVie face risks from Humira patent expiration?

Yes, AbbVie faces declining Humira revenue due to biosimilar competition.

How does Pfizer plan to offset declining COVID-19 revenue?

Pfizer aims to diversify revenue through new drug development and acquisitions.

AbbVie vs. Pfizer: Which Pharma Giant Is the Better Investment in 2026?

AbbVie and Pfizer are taking divergent paths to navigate patent expirations and competition. This analysis compares their financials, risk profiles, and valuation metrics.

June 25, 2026

2 min read

Source: Motley Fool

According to a report by Motley Fool, AbbVie (ABBV) and Pfizer (PFE) are pursuing different strategies to address patent expirations and increasing competition in the pharmaceutical market. This analysis examines their financials, risk profiles, and valuation.

Financial Performance

AbbVie relies heavily on its immunology drug Humira, which faces growing competition from biosimilars. In contrast, Pfizer benefited from COVID-19 vaccine and Paxlovid sales but is now diversifying its revenue streams.

Risk Profile

AbbVie faces the risk of declining Humira revenue, while Pfizer struggles with falling demand for COVID-19 products. Both companies are developing new pipelines to offset these challenges.

Valuation

AbbVie trades at a higher P/E ratio than Pfizer, possibly reflecting higher growth expectations. However, Pfizer offers a higher dividend yield, attracting income-focused investors.

What This Means for Investors

Investors should consider their investment goals and risk tolerance. AbbVie may suit those seeking long-term growth, while Pfizer could be better for those preferring regular income.

Frequently Asked Questions

AbbVie relies on Humira and faces biosimilar competition, while Pfizer is diversifying after declining COVID-19 product sales.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.